Perspective Therapeutics (CATX) has an average rating of buy and mean price target of $12.23, according to analysts polled by FactSet.
What else is happening in Research?
Research
HSBC Cuts Al Hammadi Holding PT, Maintains Hold Rating
HSBC on Wednesday decreased the price target for integrated healthcare group Al Hammadi Holding (SASE:4007) to 25 Saudi riyals from 30 riyals, while keeping its hold rating.
SASE:4007
Research
UBS Upgrades Man Group to Buy Rating, Raises PT
UBS on Thursday upgraded alternative investment manager Man Group (EMG.L) to buy from neutral and increased its price target to 3.65 pounds sterling from 3.35 pounds.
$EMG.L
Research
Kepler Cheuvreux Downgrades EssilorLuxottica to Reduce, Cuts PT
Kepler Cheuvreux on Thursday downgraded luxury eyewear maker EssilorLuxottica (EL.PA) to reduce from buy and decreased its price target to 135 euros from 244 euros.
$EL.PA